Now live: Pro — the full 13F research suite for serious investorsSee pricing →
ACUTA CAPITAL PARTNERS, LLC

Q1 2025 · 13F-HR

ACUTA CAPITAL PARTNERS, LLCholdings as filed

Filed 2025-05-15 · accession 0001104659-25-048878

$86.2M
Reported value
34
Positions
2025-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
67576A100OCULOCULAR THERAPEUTIX INC$8.9M10.4%1,219,724CommonSOLE
457669307INSMINSMED INC$8.1M9.38%106,074CommonSOLE
89157D105TRMLTOURMALINE BIO INC$6.5M7.53%426,882CommonSOLE
00032Q104WHWKWHITEHAWK THERAPEUTICS INC$6.1M7.04%3,410,402CommonSOLE
29337E102ELVNENLIVEN THERAPEUTICS INC$5.2M6.05%265,269CommonSOLE
89532M101TRVITREVI THERAPEUTICS INC$4.9M5.73%785,961CommonSOLE
834203309SLNOSOLENO THERAPEUTICS INC$4.8M5.56%67,136CommonSOLE
04016X101ARGXARGENX SE$4.2M4.82%7,023CommonSOLE
04351P101ASNDUSDASCENDIS PHA-ADR$3.6M4.22%23,340CommonSOLE
74006W207PRAXPRAXIS PRECISION MEDICINES I$3.3M3.83%87,141CommonSOLE
171757206CDTXCIDARA THERAPEUTICS INC$2.7M3.14%125,708CommonSOLE
H5870P102OCSOCULIS HOLDING AG$2.4M2.76%125,000CommonSOLE
76155X100RVMDREVOLUTION MEDICINES INC$2.4M2.73%66,662CommonSOLE
53635D202LQDALIQUIDIA CORPORATION$2.3M2.63%153,482CommonSOLE
10919W405DRUGBRIGHT MINDS BIOSCIENCES INC$2.2M2.50%59,748CommonSOLE
G4444H101BBOTHELIX ACQUISITION CORP II$2.1M2.45%187,257CommonSOLE
58933Y105MRKMERCK & CO$2.1M2.39%22,994CommonSOLE
86889P208SRZNSURROZEN INC$2.0M2.30%170,000CommonSOLE
28036F105EWTXEDGEWISE THERAPEUTICS INC$1.9M2.18%85,454CommonSOLE
589492107MREOMEREO BIOPHARMA GROUP PL-ADR$1.8M2.07%791,815CommonSOLE
90466Y103UNICYCIVE THERAPEUTICS INC$1.4M1.57%2,352,887CommonSOLE
G50871105JAZZJAZZ PHARMACEUTICALS PLC$1.2M1.38%9,575CommonSOLE
92337C203VSTMVERASTEM INC$1.1M1.23%176,000CommonSOLE
375558103GILDGILEAD SCIENCES INC$1.0M1.21%9,298CommonSOLE
880881107430TERNS PHARMACEUTICALS INC$898,5181.04%325,550CommonSOLE
98985Y108ZYMEZYMEWORKS INC$815,3470.95%68,459CommonSOLE
90400D108RAREULTRAGENYX PHARMACEUTICAL INC$770,9110.89%21,290CommonSOLE
92539P101VERVE THERAPEUTICS INC$743,6490.86%162,724CommonSOLE
77313F106RCKTROCKET PHARMACEUTICALS INC$555,9450.64%83,350CommonSOLE
75383L102RAPPRAPPORT THERAPEUTICS INC$164,4920.19%16,400CommonSOLE
34962G208FBRXFORTE BIOSCIENCES INC$143,3190.17%18,469CommonSOLE
04317A107ARTVARTIVA BIOTHERAPEUTICS INC$136,3680.16%45,456CommonSOLE
67080N119NUVB/WSNUVATION BIO INC -CW27$17,4940.02%90,832CommonSOLE
452CVR012ENLIVEN THERAPEUTICS INC$0115,805CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.